DMII (Drugs Made In America Acquisition II) Change In Working Capital: $-0.63 Mil (TTM As of Mar. 2026)


DMII Drugs Made In America Acquisition II Corp DMII
15 GF Score
Price $10.10
! 1 Warning Sign
View Full Analysis

What is Drugs Made In America Acquisition II Change In Working Capital?

Drugs Made In America Acquisition II DMII 15 Change In Working Capital is $-0.63 Mil as of Mar. 2026. GuruFocus rates DMII with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Drugs Made In America Acquisition II's change in working capital for the quarter that ended in Mar. 2026 was $0.03 Mil.

Drugs Made In America Acquisition II's change in working capital for the fiscal year that ended in Dec. 2025 was $-0.61 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Drugs Made In America Acquisition II Change In Working Capital Related Terms

Drugs Made In America Acquisition II Change In Working Capital Historical Data

* Premium members only.

The historical data trend for Drugs Made In America Acquisition II's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drugs Made In America Acquisition II Change In Working Capital Chart

Drugs Made In America Acquisition II Annual Data
Trend Dec24 Dec25
Change In Working Capital
0.00 -0.61

Drugs Made In America Acquisition II Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Working Capital Get a 7-Day Free Trial 0.05 -0.01 -0.57 -0.08 0.03
DMII
15GF Score
Drugs Made In America Acquisition II Corp DMII
Change In Working Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Drugs Made In America Acquisition II Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.63 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Working Capital of $-0.63 Mil mean?
Drugs Made In America Acquisition II (DMII) has a Change In Working Capital of $-0.63 Mil as of Mar. 2026. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Drugs Made In America Acquisition II.
Is Drugs Made In America Acquisition II's Change In Working Capital too high?
Drugs Made In America Acquisition II's current Change In Working Capital is $-0.63 Mil. Overall, Drugs Made In America Acquisition II has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's Change In Working Capital compare to BCSS and EVAC?
Drugs Made In America Acquisition II's Change In Working Capital of $-0.63 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Working Capital for a Diversified Financial Services company?
A good Change In Working Capital depends on the Diversified Financial Services industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Working Capital mean?
A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Drugs Made In America Acquisition II. Drugs Made In America Acquisition II's current Change In Working Capital is $-0.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current Change In Working Capital of $-0.63 Mil. The current Change In Working Capital is $-0.63 Mil. Drugs Made In America Acquisition II's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Working Capital calculated?
Change In Working Capital is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current Change In Working Capital is $-0.63 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition II Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition II Corp is a blank check Company.
15GF Score

Get the complete analysis for DMII

Change In Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.10
Price